Endovia Health Sciences, Inc. — Form 8-K
Filed September 22, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Endovia Health Sciences closed $500,000 in secured convertible debt from C/M Capital Master Fund, LP on September 22, 2026, the first tranche of a previously announced $1 million commitment. Proceeds support development of CannEpil, a cannabinoid veterinary therapeutic in FDA INAD program for canine cancer pain, and international commercialization. Filing emphasizes favorable regulatory backdrop: FDA launched botanical drug development initiative and Congress introduced H.R. 10150 (Advancing Botanical Drug Development Act) proposing 12-year market exclusivity for approved botanical drugs.
Why this rating
Funding is ~7.7% of $6.5M market cap—material for a micro-cap. Validates strategy, extends runway, and favorable regulatory environment reduces development risk.
Price action (we called it positive)
before filing · preread $0.23 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from September 22, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.